Shenzhen Neptunus Bioengineering Co., Ltd. (stock code: 000078) is a high-tech enterprise focusing on the research and development, production and sales of biomedical and health products. The company is committed to continuously improving its core competitiveness by technological innovation and product upgrades, and providing customers with high-quality health products and services. In the first quarter of 2024, Neptunus Bioengineering released its latest financial report, and this article will provide a detailed analysis of its financial data.

The total assets of Neptunus Bioengineering in the first quarter of 2024 were 32.662 billion yuan, an increase of 1.11% compared to the end of the previous year of 32.305 billion yuan. The owner's equity belonging to the shareholders of the listed company was 3.046 billion yuan, an increase of 1.42% compared to the end of the previous year of 3.003 billion yuan. The asset-liability ratio slightly increased from 86.94% at the end of the previous year to 86.97%. These data indicate that Neptunus Bioengineering has maintained steady growth in asset size and shareholder equity, but the slight increase in the asset-liability ratio also suggests that the company needs to further optimize its debt management.

In terms of profit, Neptunus Bioengineering's operating income was 8.088 billion yuan, a year-on-year decrease of 18.78%. The net income attributable to shareholders of the listed company was 426.4 million yuan, a year-on-year decrease of 42.79%. However, the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 473.7 million yuan, a year-on-year increase of 6.48%. This indicates that although overall revenue and net income have declined, the net income after deducting non-recurring gains and losses has increased, showing that the company's main business profitability has improved. The gross margin decreased from 10.69% in the same period of the previous year to 10.42%, and the net margin decreased from 1.11% to 0.86%, which reflects that the company still needs to strengthen its cost control and profitability.

In terms of cash flow, the net cash flow generated from operating activities of Neptunus Bioengineering was 56.76 million yuan, a year-on-year decrease of 48.16%. The subtotal of cash inflows from operating activities slightly decreased year-on-year to 9.411 billion yuan, while the subtotal of cash outflows slightly increased year-on-year to 9.355 billion yuan. This is mainly due to the decrease in sales receivables of the company. The net cash flow from investing activities increased by 36.76% year-on-year, mainly due to the reduction of equity payment paid in this period. The net cash flow from financing activities decreased by 147.66% year-on-year, mainly due to the repayment of bank borrowings in this period. These data indicate that the company is facing certain pressures in terms of cash flow from operating activities, but has improved in terms of cash flow from investing and financing activities.

In summary, the financial performance of Neptunus Bioengineering in the first quarter of 2024 presents certain challenges and opportunities. It has maintained steady growth in assets and shareholder equity, but faces pressure in terms of revenue and net income. The company needs to further optimize its cost control, profitability, and cash flow management to respond to market changes and competition pressures. In the future, Neptunus Bioengineering should continue to strengthen technological innovation and product upgrades, enhance core competitiveness, and achieve sustainable development.